Based on these data we hypothesize the following. Compensatory hyperinsulinemia that accompanies insulin resistance generates either a normal or a stronger-than-normal initial signal at the level ...

In other patients, it is associated with nondiabetic insulin resistance ... The classical mechanism of PKC activation is through ligand binding to G-protein-coupled receptors, which for example ...

Impaired insulin receptor signaling is strongly linked to obesity-related metabolic conditions like non-alcoholic fatty liver disease (NAFLD) and Type 2 diabetes (T2DM). However, the exact mechanisms ...

Tyrosine-protein phosphatase non-receptor type 1 (PTP1B) acts as a negative regulator of the insulin signaling pathway by dephosphorylating both the insulin receptor (IR) and the insulin receptor ...

My laboratory is interested in the molecular mechanisms by which the insulin receptor and other receptor tyrosine kinases (RTKs) are activated upon ligand binding, and the structural basis for ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...

Signal transduction mechanism of EGFR (epidermal growth factor receptor) transactivation by angiotensin II ... ADAM17 may contribute to endothelial dysfunction and insulin resistance by producing TNFα ...

Insulin-like growth factor-2 (IGF2), which is widely ... to mediate neuroprotection against increased Aβ secretion in AD mice through an IGF1 receptor-dependent mechanism (Stein and Johnson, 2002).

The mechanism of the drug's beneficial effect on cardiovascular disease remains to be determined. Recently, timed-release bromocriptine (Cycloset), a sympatholytic dopamine D 2 receptor agonist ...